TLT8
TLT8 is a ByeTAC protein degrader targeting BTK. TLT8 non-covalently binds to Rpn-13 and BTK, thereby inducing BTK degradation. TLT8 can be used in chronic lymphocytic leukemia research. (Rpn-13 ligand: HY-159808; BTK ligand: HY-Z3101; linker: HY-172823).
Product Specifications
UNSPSC
12352211
Target
Btk; ByeTAC
Related Pathways
PROTAC; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
NC1=C2C(C3=CC=C(C=C3)OC4=CC=CC=C4)=NN(C2=NC=N1)[C@H]5CCCN(C5)C(CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CC6SC7=NN=C(N7N=C6C8=CC=C(C=C8)Cl)CC9=CC=C(C=C9)Br)=O)=O)=O
Molecular Formula
C63H76BrClN12O12S
Molecular Weight
1340.77
References & Citations
[1]Loy CA, et al. ByeTAC: Bypassing E-Ligase-Targeting Chimeras for Direct Proteasome Degradation. J Med Chem. 2025 Apr 19.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-62601R-BF750 100 µL
STAMBP Recombinant Antibody, AbBy Fluor™ 750 Conjugated
Sign In for Pricing
View Details 
MBS1122493-01 0.05 mg (Mammalian-Cell)
Recombinant Zygosaccharomyces rouxii Pentafunctional AROM polypeptide (ARO1), partial
Sign In for Pricing
View Details